Product Description
Mechanisms of Action: ROCK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Microvascular Angina|Erectile Dysfunction|Coronary Artery Disease|Myocardial Ischemia|Angina, Stable
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ACT14656 | P2 |
Terminated |
Angina, Stable|Myocardial Ischemia|Coronary Artery Disease|Microvascular Angina |
2018-07-23 |
48% |
2019-03-21 |
Treatments |
| 2016-000629-38 | P2 |
Completed |
Coronary Artery Disease |
2018-07-23 |
48% |
2022-03-13 |
Treatments |
| RHOKET | P2 |
Completed |
Erectile Dysfunction |
2009-09-01 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/07/2019 |
News Article |
Sanofi delivers 2018 business EPS growth of 5.1% at CER |